Morphoea and *Borrelia burgdorferi*: results from the Scottish Highlands in the context of the world literature

**J R Goodlad, M M Davidson, P Gordon, R Billington, D O Ho-Yen**

**Aims**: Previous studies investigating the link between infection with *Borrelia burgdorferi* and morphoea have produced conflicting results. Often, these studies have been undertaken in patients from different regions or countries, and using methods of varying sensitivity for detecting *Borrelia burgdorferi* infection. This study aimed to establish whether a relation could be demonstrated in the Highlands of Scotland, an area with endemic Lyme disease, with the use of a sensitive method for detecting the organism.

**Methods**: The study was performed on biopsies of lesional skin taken from 16 patients from the Highlands of Scotland with typical clinical features of morphoea. After histological confirmation of the diagnosis, a nested polymerase chain reaction (PCR) using primers to a unique conserved region of the *Borrelia burgdorferi* flagellin gene was performed on DNA extracts from each biopsy. A literature search was also performed for comparable studies.

**Results**: None of the 16 patients had documented clinical evidence of previous infection with *B. burgdorferi*. DNA was successfully extracted from 14 of the 16 cases but all of these were negative using PCR for *B. burgdorferi* specific DNA, despite successful amplification of appropriate positive controls in every test. The results were compared with those of other documented studies.

**Conclusions**: Examination of the literature suggests that there is a strong geographical relation between *B. burgdorferi* and morphoea. These results, in which no such association was found, indicate that morphoea may not be associated with the subspecies of *B. burgdorferi* found in the Highlands of Scotland.

**Erythema chronicum migrans**, *acrodermatitis chronica atrophicans* (ACA), and *lymphocytoma cutis* are all cutaneous manifestations of Lyme disease, a multisystem disorder that follows infection with *Borrelia burgdorferi*.1,2 An aetiological role for *B. burgdorferi* has also been proposed for other skin disorders, including primary cutaneous B cell lymphoma (PCBCL) and morphoea. Although there is increasing evidence to support this hypothesis in the context of PCBCL,3 studies investigating the link between *B. burgdorferi* and morphoea have produced conflicting results, some reports suggesting a positive association, but others not.2 This has led to the proposal that regional variations in *B. burgdorferi* may be important in dictating the spectrum of clinical disease following infection, with morphoea only being caused by certain subspecies endemic to specific geographical areas.7

“Studies investigating the link between *Borrelia burgdorferi* and morphoea have produced conflicting results, some reports suggesting a positive association, but others not”

Although Lyme disease is endemic in many areas of the UK, only two previous studies have investigated the possible link with morphoea specifically in the UK.4,5 Both gave a negative result, but this was based primarily on patients with morphoea lacking serological evidence of previous infection with *B. burgdorferi*. However, because *B. burgdorferi* infection may occur without the production of specific antibodies these results are inconclusive.6 Therefore, we used a polymerase chain reaction (PCR) technique to evaluate skin biopsies taken from patients with morphoea in the Highlands of Scotland, an area with endemic Lyme disease, for the presence or absence of *B. burgdorferi* specific DNA. Recently, this approach has been used successfully to demonstrate a significant association between *B. burgdorferi* and PCBCL in patients from the same region.7 A literature review was also performed to interpret our results in the context of the possible geographical variations that may exist in the relation between *B. burgdorferi* infection and the subsequent development of morphoea.

**MATERIALS AND METHODS**

**Case selection**

The pathology department, Raigmore Hospital, Inverness, UK, processes all surgical pathology specimens for the Highland and Western Isles regions of Scotland, an area with a population of approximately 250 000 in which Lyme disease is endemic. By searching the surgical pathology files, Raigmore Hospital, Inverness (from 1976 to date), and reviewing case records of all patients with histology compatible with morphoea we were able to identify 16 patients for study, all with histological and clinical features typical of morphoea.

**Pathological studies**

Sections (5 µm thick) were cut from formalin fixed, routinely processed, paraffin wax embedded tissue blocks of each biopsy and stained with haematoxylin and eosin. Each case was assessed to confirm a diagnosis of morphoea and to approximate the stage of the disease using standard criteria.11

**Demonstration of *B. burgdorferi* DNA**

Sections (6 x 5 µm) cut from formalin fixed, paraffin wax embedded tissue blocks were dewaxed and DNA extracted using the Intergen EX-WAX DNA extraction kit (Intergen, 1994)....

**Abbreviations**: ACA, *acrodermatitis chronica atrophicans*; PCBCL, primary cutaneous B cell lymphoma; PCR, polymerase chain reaction
Manhattanville, New Jersey, USA). All DNA extracts were tested by PCR with primers for β globin to ensure that DNA of sufficient quality and quantity was obtained for subsequent analysis.

To detect *B. burgdorferi*, a nested PCR assay was used to amplify a sequence of the highly conserved flagellin encoding region, as described previously. The first stage PCR was performed with 20 µl of sample in a reaction volume of 50 µl, containing final concentrations of 10mM Tris/HCl (pH 8.5), 50mM KCl, 3.5mM MgCl2 (Applied Biotechnologies), 0.5 mM dNTP (Pharmacia Biosystems, Milton Keynes, UK), 0.3 U Taq polymerase (Applied Biotechnologies), and 0.2 µM of each primer F1 (5′-ATT AAC GCT GCT AAT CTT AGT-3′) and F3 (5′-GTA CTA TTC TTT ATA GAT TC-3′) (Severn Biotech, Kidderminster, UK). The thermal cycling conditions were 35 cycles of one minute at 94°C, two minutes at 41°C, and three minutes at 66°C, followed by a further extension period of five minutes at 72°C. For the nested PCR, 20 µl of a 1/5 dilution of the first stage product was amplified in a 50 µl reaction mix with a reduced concentration of MgCl2 (2.5mM) and primers F6 (5′-TTC AGG GTC TCA AGC GTC TTG GAC T-3′) and F8 (5′-GCA TTT TCA AIT TTA GCA AGT GAT G-3′) (Severn Biotech). The thermal cycling conditions were 35 cycles of one minute at 94°C, one minute at 50°C, and one minute at 72°C, with a final extension of five minutes at 72°C. A positive control (10 cultured *B. burgdorferi* organisms) and negative control were included in all cases. The PCR products were visualised under ultraviolet transmission of ethidium bromide stained agarose gels.

**RESULTS**

**Clinical features**

There were five male and 11 female patients ranging in age from 3 to 69 years at diagnosis. According to the classification of Peterson et al, there were 13 cases of plaque morphoea (12 morphoea en plaque, one atrophoderma of Pasini and Pierini), two cases of linear morphoea (one linear morphoea, one en coup de sabre), and one case of generalised morphoea. None of the patients had a history of antibiotic treatment in their hospital notes and none had a documented history of manifestations of Lyme disease.

**Pathological findings**

All 16 cases showed histological features consistent with a diagnosis of morphoea, the principle finding being the presence of thickened collagen bundles in the reticular dermis. The histological stage of the lesion was approximated by additional changes. Three cases were interpreted as early stage lesions. All displayed a moderate lymphocytic infiltrate with fewer numbers of plasma cells arranged around blood vessels lined by swollen endothelial cells (fig 1). Six biopsies were regarded as showing features of late stage lesions. In these, there was increased eosinophilia of the thickened collagen bundles, together with homogenouse collagen in the papillary dermis, atrophy of eccrine glands with marked loss of periglandular fat, some fibrous thickening of blood vessel walls, and a minimal or absent chronic inflammatory cell infiltrate (fig 2). The remaining seven cases displayed features in keeping with lesions of an intermediate duration in which the "late" changes were either less pronounced, or only some were present.

**PCR analysis**

Amplifiable DNA was obtained from 14 of the 16 biopsies, as determined by PCR with primers for β globin. These 14 cases were tested using primers for the *B. burgdorferi* flagellin gene. In each test, there was successful amplification of control DNA extracted from cultured borrelia organisms, giving a product of 275 bp after the nested run. However, all 14 samples from patients with morphoea were negative, as were the negative controls (fig 3).
including 53 patients included in two studies from the 
patients with morphoea tested have been seronegative, 
dence of previous infection and sought to correlate this with 
patients with morphoea may display specific cellular 
staining or immunohistochemistry have met with mixed suc-
borellia organisms directly in histological sections after silver 
strate the organism in biopsies of lesional skin taken from 
more definite evidence of a causal link by seeking to demon-
merely represent coincidental infection, other studies sought 
evaluating positive results using these methodologies, recent 
manifestation of chronic borreliosis.

The suspicion that morphoea may occur as a consequence of 
was initially aroused by clinical 
observations of coexisting morphoea and ACA, a cutaneous 
B burgdorferi 
in between 6% and 54% of 
positive culture where spirochaetes have been subtyped; in this instance PCR analysis confirmed 
spirochaetes have been subtyped; in this instance PCR analysis confirmed 
induced proliferation of peripheral blood lymphocytes. †This represents the only 
induced proliferation of peripheral blood lymphocytes. †This represents the only 
Serology 

<table>
<thead>
<tr>
<th>Reference</th>
<th>Country</th>
<th>Direct visualisation in tissue sections of morphoea biopsies</th>
<th>Serology</th>
<th>Culture from biopsies of morphoeic lesions</th>
<th>PCR analysis of DNA extracts of morphoea biopsies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aberer and Staneck (1987)</td>
<td>Austria</td>
<td>4/13 (immunoperoxidase)</td>
<td>7/13</td>
<td>1/3</td>
<td>ND</td>
</tr>
<tr>
<td>Breier et al (1996)</td>
<td>Austria</td>
<td>ND</td>
<td>13/39*</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Aberer et al (1996)</td>
<td>Austria</td>
<td>4/16 (immunoperoxidase)</td>
<td>ND</td>
<td>0/22</td>
<td>ND</td>
</tr>
<tr>
<td>Breier et al (1999)</td>
<td>Austria</td>
<td>0/1 (silver stain)</td>
<td>1/11</td>
<td>1/11</td>
<td>ND</td>
</tr>
<tr>
<td>Schempf et al (1993)</td>
<td>Germany</td>
<td>ND</td>
<td>0/5</td>
<td>ND</td>
<td>9/9</td>
</tr>
<tr>
<td>Wientje et al (1995)</td>
<td>Germany</td>
<td>4/18</td>
<td>ND</td>
<td>0/30</td>
<td>ND</td>
</tr>
<tr>
<td>Weide et al (2000)</td>
<td>Germany</td>
<td>3/53</td>
<td>ND</td>
<td>0/33</td>
<td>ND</td>
</tr>
<tr>
<td>Weber et al (1988)</td>
<td>Germany</td>
<td>0/2</td>
<td>2/2</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Muhlemann et al (1986)</td>
<td>UK</td>
<td>0/22</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Lupoli et al (1991)</td>
<td>UK</td>
<td>ND</td>
<td>0/31</td>
<td>0/9</td>
<td>ND</td>
</tr>
<tr>
<td>Raguin et al (1992)</td>
<td>France</td>
<td>0/14 (immunoperoxidase)</td>
<td>0/15</td>
<td>0/10</td>
<td>ND</td>
</tr>
<tr>
<td>Meiss et al (1993)</td>
<td>Holland</td>
<td>0/2</td>
<td>0/12</td>
<td>0/12</td>
<td>ND</td>
</tr>
<tr>
<td>Ranke et al (1994)</td>
<td>Finland</td>
<td>1/7</td>
<td>ND</td>
<td>0/7</td>
<td>ND</td>
</tr>
<tr>
<td>Alonso-Llamazares et al (1997)</td>
<td>Spain</td>
<td>0/1</td>
<td>0/6</td>
<td>0/6</td>
<td>ND</td>
</tr>
<tr>
<td>Trevisan et al (1996)</td>
<td>Italy</td>
<td>3/10</td>
<td>ND</td>
<td>1/11</td>
<td>ND</td>
</tr>
<tr>
<td>Buchner et al (1997)</td>
<td>Switzerland</td>
<td>10/10§</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Otskan et al (2000)</td>
<td>Turkey</td>
<td>ND</td>
<td>1/9</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Ross et al (1990)</td>
<td>Puerto Rico</td>
<td>0/10 (silver stain)</td>
<td>0/15</td>
<td>0/10</td>
<td>ND</td>
</tr>
<tr>
<td>Fujii et al (1997)</td>
<td>Japan</td>
<td>ND</td>
<td>2/10</td>
<td>2/10</td>
<td>ND</td>
</tr>
<tr>
<td>Fujii et al (1997)</td>
<td>USA</td>
<td>ND</td>
<td>1/11</td>
<td>1/11</td>
<td>ND</td>
</tr>
<tr>
<td>Daoud et al (1994)</td>
<td>USA</td>
<td>0/10 (silver stain)</td>
<td>0/10</td>
<td>0/10</td>
<td>ND</td>
</tr>
<tr>
<td>Fan et al (1995)</td>
<td>USA</td>
<td>ND</td>
<td>0/10</td>
<td>0/10</td>
<td>ND</td>
</tr>
<tr>
<td>Dillon et al (1995)</td>
<td>USA</td>
<td>ND</td>
<td>0/10</td>
<td>0/10</td>
<td>ND</td>
</tr>
<tr>
<td>De Vito et al (1996)</td>
<td>USA</td>
<td>ND</td>
<td>0/10</td>
<td>0/10</td>
<td>ND</td>
</tr>
<tr>
<td>Colome-Grimmer et al (1997)</td>
<td>USA</td>
<td>ND</td>
<td>0/10</td>
<td>0/10</td>
<td>ND</td>
</tr>
</tbody>
</table>

*Eleven of 39 cases in this study also showed an increased B burgdorferi induced proliferation of peripheral blood lymphocytes. †This represents the only 
positive culture where spirochaetes have been subtyped; in this instance PCR analysis confirmed 
induced proliferation of peripheral blood lymphocytes. †This represents the only 

**Table 1** Summary of previous studies investigating the relation between *Borrelia burgdorferi* infection and morphoea in different geographical locations

**Literature review**

Table 1 summarises the results of the literature review. 14–37

**DISCUSSION**

The suspicion that morphoea may occur as a consequence of infection with *B burgdorferi* was initially aroused by clinical observations of coexisting morphoea and ACA, a cutaneous manifestation of chronic borreliosis. 14–18 Subsequently, several different methodologies have been used to investigate this relation, often with confusing and conflicting results (table 1). Initially, studies used positive serology for *B burgdorferi* as evidence of previous infection and sought to correlate this with clinical manifestations of morphoea. In several series, all patients with morphoea tested have been seronegative, including 53 patients included in two studies from the UK. 19, 20 Conversely, other studies have found specific antibodies to *B burgdorferi* in between 6% and 54% of unselected patients with morphoea. 14–16, 18–20 22, 23, 25, 26 In addition to a humoral immune response to the organism, large numbers of patients with morphoea may display specific cellular immunoreactivity. 14–16

Because negative serology does not exclude previous infection with *B burgdorferi* and because positive serology may merely represent coincidental infection, other studies sought more definite evidence of a causal link by seeking to demonstrate the organism in biopsies of lesional skin taken from patients suffering from morphoea. Attempts to visualise borrelia organisms directly in histological sections after silver staining or immunohistochemistry have met with mixed success, and in only a small number of cases have spirochaetes been demonstrated. 14, 15, 17, 19, 20, 25, 26, 27 In view of problems in evaluating positive results using these methodologies, recent studies have focused on more sensitive and specific PCR techniques to demonstrate the organism. Once more the results have been contradictory. Studies reporting a positive association between *B burgdorferi* infection and morphoea have shown evidence of the organism in between 26% and 100% of cases, 14–37 whereas in a further 10 reports, including our current one, no positive cases have been identified in a total of 190 cases tested. 14–37 Lastly, the culture of borrelia from biopsies of morphoeic lesions has also been attempted. Although several studies have produced completely negative results, 14–16, 25, 26, 28 success has been achieved in a small number of cases, 14–16, 17, 19, 20, 24 and the negative results may be partly or wholly attributable to the fastidiousness of the organism in culture.

Two possible conclusions can be drawn from this diaspora of results. The less charitable argument is that all of the positive findings reported are the result of one or more of the following: clinical and/or histological misdiagnosis of ACA; morphoea, because both entities share several common features; the chance occurrence of *B burgdorferi* infection and morphoea, especially in cases from areas of endemic Lyme disease; the presence of another causative agent that may be transmitted at the same time as *B burgdorferi*; and contamination of samples, especially with regard to PCR studies. However, it is difficult to envisage that all positive results to date can be explained in this way. This is particularly so for one group of Austrian researchers who have consistently found positive titres for *B burgdorferi* in a significantly higher proportion of patients with morphoea than in controls, and who have successfully demonstrated *B burgdorferi* in biopsies of morphoeic skin by immunohistodiagnosis of ACA, with specific antibodies, in addition to the use of culture and typing. 14–20 If the positive results are taken at face value then an alternative
explanation, as previously proposed, is that subspecies variations in *B. burgdorferi*, which occur between different geographical locations, dictate the clinical manifestations that follow infection, with only certain strains possessing the characteristics required to initiate the development of morphoea. This phenomenon is already well documented for other accepted facets of borrelia infection. For example, ACA rarely occurs during the course of Lyme disease in North America where *B. burgdorferi* sensu stricto is the dominant species, but is commonly seen in Europe where *B. afzelii* and *B. garinii* are more prevalent.55

“These results indicate that in the Scottish Highlands there is no association between infection with indigenous strains of *Borrelia burgdorferi* and the subsequent development of morphoea”

If this hypothesis is correct, then the literature suggests that *B. burgdorferi* is implicated in the pathogenesis of at least some cases of morphoea in Austria (especially in the vicinity of Vienna). However, the data currently available do not disprove this theory. We have recently typed 12 isolates of *B. burgdorferi* from archival material from patients with PCBCL. Although PCR is prone to false negative results, our technique has been sufficiently sensitive to have detected the organism were it present. Positive controls were amplified in each reaction and we have also used this technique to identify *B. burgdorferi* in archival material from patients with PCBC1. In addition, our cases were not biased towards late stage morphoea and, coupled with the fact that *B. burgdorferi* has been identified in biopsies of patients with morphoea up to 20 years after the onset of cutaneous lesions, this means that the age of the lesions sampled was unlikely to have produced a false negative result. Moreover, although not directly questioned, there was no evidence that our patients were receiving antibiotic treatment before biopsy and none had a history documenting previous manifestations of Lyme disease. These results indicate that in the Scottish Highlands there is no association between infection with indigenous strains of *B. burgdorferi* and the subsequent development of morphoea.

Whether or not this negative result is entirely attributable to the particular strains of *B. burgdorferi* encountered in the highlands, as compared with Austria, remains to be determined. However, the data currently available do not disprove this theory. We have recently typed 12 isolates of *B. burgdorferi* sensu lato grown from highland ticks, five as *B. afzelii* and seven as *B. burgdorferi* sensu stricto, and discovered two different strains of the first organism and four of the second. Of particular interest to our current study was the finding that all strain types differed from reference strains derived from mainland Europe. In fact, such genomic heterogeneity appears to be normal, both within and between geographical areas.56 In view of this, and considering the expanding spectrum of disease attributed to *B. burgdorferi*, further studies are warranted to investigate the effect of strain type on the clinical manifestations of infection.

ACKNOWLEDGEMENTS

This work was partly funded by a grant from Raigmore Hospital, Research and Endowments Fund and partly funded by grant K/ MRS/50/C2774 awarded by the Chief Scientist Office, Edinburgh. The authors would also like to thank Dr J McPhie, Head of Pathology, Raigmore Hospital, Inverness, for his support and I Christie for technical assistance.

Authors’ affiliations

J R Goodlad, Billington R, Department of Pathology, Highland Acute Hospitals NHS Trust, Raigmore Hospital, Inverness IV2 3UJ, UK

M M Davidson, D O Ho-Yen, Department of Microbiology, Highland Acute Hospitals NHS Trust

P Gordon, Department of Dermatology, Highland Acute Hospitals NHS Trust

REFERENCES


New JCP online submission and review system

We are pleased to inform authors and reviewers of the new online submission and review system at JCP. Developed by HighWire Press (CA, USA), Bench Press is a fully integrated electronic system that utilizes the web to allow rapid and efficient submission of manuscripts. It also allows the peer review process to be conducted entirely online. We are one of the first journals in the BMJ Special Journals group to go online in this way. The aim, apart from saving trees, is to speed up the often frustratingly slow process (for both authors and editors) from submission to publication. Many reviewers might appreciate this too.

Authors may submit their manuscript in any standard word processing software. Acceptable standard graphic formats include: jpeg, tiff, gif, and eps. The text and graphic files are automatically converted to PDF for ease of distribution and reviewing purposes.

To access the system click on “SUBMIT YOUR MANUSCRIPT HERE” on the JCP homepage: HYPERLINK http://www.jclinpath.com, or you can access Bench Press directly at HYPERLINK http://submit-jcp.bmjjournals.com.

We are very excited with this new development and would encourage authors and reviewers to use the online system whenever possible. As editors, we will use it all the time, the up side being lack of need to travel to the editorial office to deal with papers, the down side having no more excuses to postpone decisions on papers because we are “at a meeting”!

The system is very easy to use and should be a big improvement on the current peer review process. Full instructions can be found on Bench Press http://submit-jcp.bmjjournals.com and JCP online at http://www.jclinpath.com. Please contact Natalie Davies, Project Manager, HYPERLINK mailto:ndavies@bmjjournals.com for any further information.

H Holzel, P van Diest